C&L: Drakeman resigns from Medarex

Medarex CEO Donald Drakeman (photo) resigned his post as the company issued new findings in its investigation of how stock options were granted over the past 10 years.

Bradford A. Zakes was named president and CEO of ImaRx Therapeutics.

ARCA Discovery has named Richard B. Brewer president and CEO.

Meiken Krebs has been appointed president and CEO of EMD Chemicals has.

Excel Life Sciences has hired Dr. Vijai Kumar as the company's president and chief medical officer.

Acumen Pharmaceuticals has promoted Dr. William F. Goure to the post of COO.

Scott McCallister, M.D. has joined Panacos Pharmaceuticals as chief medical officer.

Invitrogen Corporation promoted Bernd Brust to the newly-created position of senior vice president of sales for Europe and the Americas.

Ciphergen Biosystems named Debra A. Young vice president and CFO.

Symphogen has named Christian Meyer, M.D., Ph.D., vice president of clinical development.

Daniel B. Soland has joined the Viropharma as its vice president and COO.

Mark Longer, Ph.D., has joined Napo Pharmaceuticals as its vice president, program planning and management.

Dynavax Technologies named Michael Ostrach as VP, chief business officer and general counsel.

Pharmacopeia has appointed Rene Belder, M.D., as vice president, clinical and regulatory affairs.

KAI Pharmaceuticals has named Dirk B. Mendel, Ph.D. as vice president of pharmacology & preclinical pharmacokinetics and pharmacodynamics.

Compugen has appointed Eli Zangvil, MD, as vice president, business development.

AtheroGenics named J. Christopher Prue, RPh to the position of vice president, regulatory affairs.

Inimex Pharmaceuticals has named Dr. K. Jeffry Wilson as vice president of product development.

BioInformatics has appointed Rowena Roberts, Ph.D. as director of marketing and sales.

Aradigm Corporation has appointed John M. Siebert, Ph.D. to the board of directors.

King Pharmaceuticals named Philip A. Incarnati to the company's board of directors.

MacuSight has named Brian C. Cunningham to its board of directors.

SpeciGen has named David Goldsteen, MD, to its board of directors.

BioXell announced that Thomas Szucs, member of its board of directors, has been appointed chairman of the board, replacing Michael Steinmetz who will remain on the board.

Ikonisys has appointed J. Timothy Corcoran to its board of directors.

National Stem Cell Holding announced that Michael J. Shamblott, Ph.D., a founding member of the Johns Hopkins University School of Medicine's Institute for Cell Engineering, has been named the company's chief scientific advisor.

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.